|
|
|
| Dec. 29, 2011 |
FDA to Review Potential New Use of XGEVA® (Denosumab) at Oncologic Drugs Advisory Committee Meeting
|
| Dec. 19, 2011 |
Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars
|
| Dec. 15, 2011 |
Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
|
| Dec. 15, 2011 |
Amgen Announces 2012 First Quarter Dividend
|
| Dec. 14, 2011 |
Amgen Announces Final Results of Its Tender Offer
|
| Dec. 13, 2011 |
Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
|
| Dec. 9, 2011 |
Amgen to Present at the 22nd Annual Oppenheimer Healthcare Conference
|
| Dec. 8, 2011 |
Amgen Announces Preliminary Results of Its Tender Offer
|
| Dec. 6, 2011 |
Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
|
| Nov. 22, 2011 |
Enbrel® (etanercept) Patent Issued
|
| Nov. 15, 2011 |
The Lancet Publishes Results Demonstrating XGEVA® Significantly Prolonged Bone Metastasis-free Survival in Men With Prostate Cancer
|
| Nov. 15, 2011 |
Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
|
| Nov. 14, 2011 |
Amgen Statement on European Investor Visit
|
| Nov. 7, 2011 |
Amgen Announces Plan to Launch Tender Offer and Launch of Senior Notes Offering
|
| Nov. 5, 2011 |
Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease
|
| Nov. 5, 2011 |
Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial
|
| Oct. 24, 2011 |
Amgen's Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
|
| Oct. 19, 2011 |
Amgen Announces Webcast of 2011 Third Quarter Financial Results
|
| Oct. 19, 2011 |
Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
|
| Oct. 13, 2011 |
Amgen Appoints Robert A. Bradway to the Company's Board of Directors
|
| Oct. 13, 2011 |
Amgen Announces 2011 Fourth Quarter Dividend
|
| Sep. 23, 2011 |
Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress
|
| Sep. 19, 2011 |
FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
|
| Sep. 17, 2011 |
Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
|
| Sep. 15, 2011 |
Amgen to Present at the UBS Global Life Sciences Conference
|
| Sep. 15, 2011 |
Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits
|
| Sep. 12, 2011 |
Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
|
| Sep. 8, 2011 |
Amgen to Present at the Morgan Stanley Global Healthcare Conference
|
| Sep. 6, 2011 |
Amgen to Present at the Baird Healthcare Conference
|
| Sep. 2, 2011 |
Amgen to Present at the Stifel Nicolaus Healthcare Conference
|
| Aug. 25, 2011 |
Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign
|
| Aug. 22, 2011 |
Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
|
| Aug. 18, 2011 |
Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
|
| Jul. 29, 2011 |
Amgen's Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
|
| Jul. 25, 2011 |
Amgen Announces Webcast of 2011 Second Quarter Financial Results
|
| Jul. 15, 2011 |
Amgen Resolves G-CSF Patent Litigation With Teva
|
| Jul. 15, 2011 |
XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
|
| Jul. 5, 2011 |
Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss
|
| Jun. 27, 2011 |
Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
|
| Jun. 24, 2011 |
Notice to Investors Regarding 2011 and 2015 Guidance
|
| Jun. 24, 2011 |
Amgen Announces Modifications to U.S. Prescribing Information for Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease
|
| Jun. 24, 2011 |
Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
|
| Jun. 21, 2011 |
Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
|
| May. 25, 2011 |
Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel(R) (etanercept) for Patients with Chronic Inflammatory Conditions
|
| May. 20, 2011 |
Amgen Announces Voting Results Of Annual Meeting of Stockholders
|
| May. 20, 2011 |
Amgen Receives CHMP Positive Opinion for XGEVA(TM) (Denosumab) in the European Union
|
| May. 18, 2011 |
Amgen Oncology Data to be Presented at ASCO Annual Meeting
|
| May. 17, 2011 |
Phase 3 Data Demonstrate XGEVA(TM) (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer
|
| May. 13, 2011 |
Amgen to Webcast Investor Meeting at Upcoming American Urological Association Conference
|
| May. 11, 2011 |
Patrick Dempsey Teams up With Breakaway from Cancer(R) to Help Connect Cancer Patients to Free Resources
|
| May. 10, 2011 |
Five Californians Selected as Breakaway from Cancer(R) Champions to be Honored During Amgen Tour of California
|
| Apr. 28, 2011 |
Amgen to Present at the Deutsche Bank 36th Annual Healthcare Conference
|
| Apr. 21, 2011 |
Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans
|
| Apr. 21, 2011 |
Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
|
| Apr. 20, 2011 |
Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
|
| Apr. 14, 2011 |
Amgen to Webcast 2011 Business Review Meeting on April 21
|
| Apr. 13, 2011 |
Amgen Announces Webcast of 2011 First Quarter Financial Results
|
| Apr. 8, 2011 |
Amgen Establishes Commercial Operations in Brazil
|
| Mar. 30, 2011 |
Amgen to Appeal CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
|
| Mar. 30, 2011 |
Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients
|
| Mar. 23, 2011 |
Prolia(R) (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
|
| Mar. 23, 2011 |
Treatment With Prolia(R) (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
|
| Mar. 18, 2011 |
Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
|
| Mar. 14, 2011 |
Amgen Donates $1 Million to Help Japanese Disaster Victims
|
| Mar. 4, 2011 |
Amgen Completes Acquisition of BioVex
|
| Mar. 3, 2011 |
Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference
|
| Mar. 3, 2011 |
Breakaway From Cancer(R) Launches Newly-Enhanced Website Offering Comprehensive, Tailored Support for Cancer Patients
|
| Mar. 2, 2011 |
World-Class Professional Golfer Phil Mickelson Launches 'On Course with Phil' for People with Certain Inflammatory Joint and Skin Conditions
|
| Mar. 1, 2011 |
NBPTS and Amgen Foundation Join to Bolster Science Education
|
| Feb. 24, 2011 |
Results Published in The Lancet Demonstrate Superiority of XGEVA(TM) (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
|
| Feb. 24, 2011 |
Amgen to Present at the Citi 2011 Global Healthcare Conference
|
| Feb. 22, 2011 |
The Journal of Clinical Oncology Publishes Phase 3 XGEVA(TM) (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
|
| Feb. 4, 2011 |
Enbrel(R) (etanercept) Significantly Improved Scalp Involvement in Patients with Moderate to Severe Plaque Psoriasis
|
| Jan. 24, 2011 |
Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
|
| Jan. 24, 2011 |
Amgen's Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
|
| Jan. 24, 2011 |
Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results
|
| Jan. 18, 2011 |
Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility
|
| Jan. 7, 2011 |
Sensipar(R) Patents Upheld By District Court
|
| Jan. 6, 2011 |
Amgen to Present at the 29th Annual JP Morgan Healthcare Conference
|
| Jan. 6, 2011 |
Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases
|
|
|
|
|
|
|
|
|
|
|
|
